Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

U16

PreclinicalSmall molecule

SShanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Relapsed or Refractory Non-Hodgkin LymphomaRecruiting

Relapsed or Refractory Non-Hodgkin LymphomaPreclinical

Recruiting

Timeline

Expected Milestones

Q4 2030

PreclinicalRecruiting

Relapsed or Refractory Non-Hodgkin Lymphoma

NCT05768529

Clinical

Trials by Indication[1]

Relapsed or Refractory Non-Hodgkin Lymphoma1 trial

A Single-arm, Open and Multicenter Phase I/II Clinical Study to Evaluate the Safety and Efficacy of U16 Injection in the Treatment of Refractory/Recurrent B-cell Non-Hodgkin's Lymphoma (r/r B-NHL)

Recruiting·SShanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd·Preclinical·NCT05768529·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for U16. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — U16 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for U16. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SShanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Related News